RESUMO
The use of herbal supplements that promise to improve immune health has gained popularity among dermatology patients. However, there is little to no evidence that herbal supplements improve dermatologic conditions. Several in vitro and in vivo studies have shown that Spirulina platensis, Aphanizomenon flos-aqua, Chlorella, Echinacea, and alfalfa activate immune cells via certain cytokines and chemokines. Case reports suggest the association of ingesting immunostimulatory herbs and the clinical onset or flares of diseases characterized by an exaggerated immune response such as lupus erythematosus, dermatomyositis, and autoimmune blistering disorders. Therefore, it is imperative to investigate the prevalence of herbal supplement use in this patient population. In addition, in vitro studies should examine the underlying mechanisms by which herbs stimulate immune pathways that are already overactive in autoimmune patients.
Assuntos
Adjuvantes Imunológicos/efeitos adversos , Doenças Autoimunes/induzido quimicamente , Suplementos Nutricionais/efeitos adversos , Dermatopatias/induzido quimicamente , Adjuvantes Imunológicos/farmacologia , Animais , Aphanizomenon , Doenças Autoimunes/imunologia , Doenças Autoimunes/fisiopatologia , Chlorella , Citocinas/metabolismo , Progressão da Doença , Echinacea/efeitos adversos , Humanos , Medicago sativa/efeitos adversos , Dermatopatias/imunologia , Dermatopatias/fisiopatologia , SpirulinaRESUMO
Echinacea purpurea, Echinacea angustifoli and Echinacea pallida are frequently used as medicinal plants. Besides asking for evidence on their efficacy, there is an increasing interest for safety data. This review systematically presents the available literature on drug interactions, contraindications, adverse events, duration of use, and safety of use in pregnant and nursing women, and assesses the safety profile of corresponding Echinacea preparations. It is noteworthy that all safety data reported are as product specific as the pharmacological or efficacy data are. In pharmacokinetic herb-drug interaction studies performed in vivo, no significant inhibitions of human CYP2D6 and CYP3A4 isoforms have been found after the administration of standardized E. purpurea preparations. However, contradictory results exist in studies using liver microsomes. Adverse events reported during clinical trials following administration of Echinacea spp. mono-preparations were generally mild and mostly without causality. Due to published long term studies with continuous ingestion of different Echinacea preparations up to 6 month with no reported toxicological concerns, Echinacea can be recommended also for long-term use. Moreover, the contraindications in cases of autoimmune diseases and immune-suppression are questionable, since lipophilic Echinacea preparations containing alkamides suppress cellular immune responses, and beneficial effects in autoimmunity were reported. The same applies for the use during pregnancy. Although there has been some impact reported on embryonic angiogenesis in mice, no association with an increased risk for major or minor malformations during organogenesis was found in a literature review. Altogether, the different evaluated Echinacea preparations are well-tolerated herbal medicines in the management in children and adults alike.
Assuntos
Echinacea , Interações Ervas-Drogas , Extratos Vegetais/efeitos adversos , Extratos Vegetais/uso terapêutico , Animais , Qualidade de Produtos para o Consumidor , Echinacea/efeitos adversos , Feminino , Humanos , Fitoterapia , Extratos Vegetais/farmacologia , GravidezRESUMO
This review focuses on contact dermatitis as an adverse effect of a selection of topically used herbal medicinal products for which the European Medicines Agency has completed an evaluation up to the end of November 2013 and for which a Community herbal monograph has been produced. Part 2: Echinacea purpurea Moench-Lavandula angustifolia Mill.
Assuntos
Dermatite de Contato/etiologia , Echinacea/efeitos adversos , Lavandula/efeitos adversos , Preparações de Plantas/efeitos adversos , Europa (Continente) , Hamamelis/efeitos adversos , Hedera/efeitos adversos , Humanos , Humulus/efeitos adversos , Hypericum/efeitos adversos , Juniperus/efeitos adversosRESUMO
BACKGROUND: Echinacea is widely used to treat the common cold. OBJECTIVE: To assess the potential benefits of echinacea as a treatment of common cold. DESIGN: Randomized, controlled trial. (ClinicalTrials.gov registration number: NCT00065715) SETTING: Dane County, Wisconsin. PATIENTS: 719 patients, aged 12 to 80 years, with new-onset common cold. INTERVENTION: Patients were assigned to 1 of 4 parallel groups: no pills, placebo pills (blinded), echinacea pills (blinded), or echinacea pills (unblinded, open-label). Echinacea groups received the equivalent of 10.2 g of dried echinacea root during the first 24 hours and 5.1 g during each of the next 4 days. Indistinguishable placebo tablets contained only inert ingredients. MEASUREMENTS: The primary outcome was the area under the curve for global severity, with severity assessed twice daily by self-report using the Wisconsin Upper Respiratory Symptom Survey, short version. Secondary outcomes included interleukin-8 levels and neutrophil counts from nasal wash, assessed at intake and 2 days later. RESULTS: Of the 719 patients enrolled, 713 completed the protocol. Mean age was 33.7 years, 64% were female, and 88% were white. Mean global severity was 236 and 258 for the blinded and unblinded echinacea groups, respectively; 264 for the blinded placebo group; and 286 for the no-pill group. A comparison of the 2 blinded groups showed a 28-point trend (95% CI, -69 to 13 points) toward benefit for echinacea (P = 0.089). Mean illness duration in the blinded and unblinded echinacea groups was 6.34 and 6.76 days, respectively, compared with 6.87 days in the blinded placebo group and 7.03 days in the no-pill group. A comparison of the blinded groups showed a nonsignificant 0.53-day (CI, -1.25 to 0.19 days) benefit (P = 0.075). Median change in interleukin-8 levels and neutrophil counts were also not statistically significant (30 ng/L and 1 cell/high-power field [hpf] in the no-pill group, 39 ng/L and 1 cell/hpf in the blinded placebo group, 58 ng/L and 2 cells/hpf in the blinded echinacea group, and 70 ng/L and 1 cell/hpf in the open-label echinacea group). LIMITATION: Higher-than-expected variability limited power to detect small benefits. CONCLUSION: Illness duration and severity were not statistically significant with echinacea compared with placebo. These results do not support the ability of this dose of the echinacea formulation to substantively change the course of the common cold. PRIMARY FUNDING SOURCE: National Center for Complementary and Alternative Medicine, National Institutes of Health.
Assuntos
Resfriado Comum/tratamento farmacológico , Echinacea , Fitoterapia , Extratos Vegetais/uso terapêutico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Resfriado Comum/imunologia , Echinacea/efeitos adversos , Feminino , Humanos , Interleucina-8/sangue , Contagem de Leucócitos , Masculino , Pessoa de Meia-Idade , Neutrófilos , Cooperação do Paciente , Relações Médico-Paciente , Fitoterapia/efeitos adversos , Efeito Placebo , Extratos Vegetais/efeitos adversos , Estudos Prospectivos , Projetos de Pesquisa , Índice de Gravidade de Doença , Adulto JovemAssuntos
Echinacea/efeitos adversos , Edema/induzido quimicamente , Dermatoses Faciais/induzido quimicamente , Preparações de Plantas/efeitos adversos , Eritema/induzido quimicamente , Humanos , Lactonas/efeitos adversos , Masculino , Pessoa de Meia-Idade , Parestesia/induzido quimicamente , Recidiva , Sesquiterpenos/efeitos adversosRESUMO
Echinacea, believed by herbal practitioners to enhance the immune system, is one of the most widely used herbal supplements in the United States. Like most herbal products, it lacks strict FDA regulation and more information is needed about its potential adverse reactions. Here, we report the case of a patient with eosinophilia of unclear etiology whose condition resolved after cessation of this supplement. We feel this likely represents an IgE-mediated allergic process to echinacea.
Assuntos
Hipersensibilidade a Drogas/etiologia , Echinacea/efeitos adversos , Síndrome Hipereosinofílica/induzido quimicamente , Fitoterapia/efeitos adversos , Preparações de Plantas/efeitos adversos , Humanos , Masculino , Pessoa de Meia-IdadeAssuntos
Echinacea/efeitos adversos , Falência Hepática Aguda/induzido quimicamente , Falência Hepática Aguda/diagnóstico , Análise Química do Sangue , Pré-Escolar , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Seguimentos , Humanos , Testes de Função Hepática , Doenças Raras , Medição de Risco , Índice de Gravidade de Doença , Ultrassonografia DopplerRESUMO
Most medications, herbal preparations, and nutraceutical supplements have notable effects on biochemical pathways and may influence wound healing, coagulation, and cardiovascular function. They can also interact with other drugs. A large portion of the data available regarding the effects of naturopathic medicines is anecdotal. Marketing of certain products may be misleading and potentially harmful, and quality control standards are highly variable. In order to ensure quality control and standardization of products, it is prudent to work with preparations manufactured by companies that adhere to pharmaceutical (good manufacturing practice [GMP]) standards. However, many of these higher-quality products are not readily available to the public over the counter. A large percentage of patients undergoing plastic surgery use one or more herbal medications, but the disclosure of such medications to allopathic providers is often incomplete. In addition, patients may not understand the importance of discontinuing such medications before surgery. The authors review research on the possible benefits and risks of commonly used herbal medications such as arnica montana, St. John's wort, bromelain, echinacea, ginkgo biloba, ephedra, valerian, and others, focusing on their potentially positive or negative impact during the perioperative period of aesthetic surgery. Good communication with surgical patients, including the administration of a presurgical questionnaire to help identify any use of herbal medications, is emphasized.
Assuntos
Suplementos Nutricionais/efeitos adversos , Assistência Perioperatória , Preparações de Plantas/efeitos adversos , Procedimentos de Cirurgia Plástica , Arnica/efeitos adversos , Arnica/metabolismo , Bromelaínas/efeitos adversos , Bromelaínas/metabolismo , Interações Medicamentosas , Echinacea/efeitos adversos , Echinacea/metabolismo , Ephedra/efeitos adversos , Ephedra/metabolismo , Ginkgo biloba/efeitos adversos , Ginkgo biloba/metabolismo , Interações Ervas-Drogas , Humanos , Hypericum/efeitos adversos , Hypericum/metabolismo , Preparações de Plantas/metabolismo , Controle de Qualidade , Cirurgia Plástica , Valeriana/efeitos adversos , Valeriana/metabolismoRESUMO
OBJECTIVE: Assessing adverse drug reactions (ADRs) is a proven method to estimate the safety of medicines. The ADRs to herbal medicines in Australia (and by inference, the safety of herbal medicines in Australia) remain unknown. This study examines spontaneous ADR cases to four of the most popular herbs in Australia from 2000 to 2015: echinacea (Echinacea purpurea), valerian (Valeriana officinalis), black cohosh (Actaea racemosa) and ginkgo (Ginkgo biloba). METHODS: ADRs of echinacea, valerian, black cohosh and ginkgo reported to the Australian Therapeutic Goods Administration (TGA) between 2000 and 2015 were obtained from the TGA database. Data were collated and analysed according to age, sex, severity, type of ADR and body system affected. Statistics were calculated using GraphPad Prism software. RESULTS: Most ADRs were mild or moderate. However, every herbal medicine was associated with life-threatening ADRs. In each life-threatening case, the herbal medicine was taken concomitantly with prescription medications. Black cohosh was associated with a significant number of severe ADRs (30.3% of the total), with 39.4% of these ADRs being associated with abnormal hepatic function, hepatitis or hepatotoxicity. CONCLUSION: This study highlights the lack of public awareness with regard to herb-drug interactions, since most of the severe ADRs involved a herb-drug interaction.
Assuntos
Cimicifuga/efeitos adversos , Echinacea/efeitos adversos , Ginkgo biloba/efeitos adversos , Interações Ervas-Drogas , Preparações de Plantas/efeitos adversos , Valeriana/efeitos adversos , Adulto , Idoso , Austrália/epidemiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Plantas Medicinais/efeitos adversosRESUMO
BACKGROUND: Concerns have been raised about the sufficiency of dietary botanical supplement (DBS) surveillance in the US. The Food and Drug Administration's Center for Food Safety and Applied Nutrition's Adverse Event Reporting System (CAERS) represents one of the few existing surveillance mechanisms, but it has not been well characterized with respect to DBS adverse effects. OBJECTIVE: To characterize data on DBSs associated with adverse event reports submitted to CAERS. METHODS: We requested and obtained CAERS data from 1999 to 2003 involving adverse effects associated with the 6 most frequently used DBSs: Echinacea, ginseng, garlic, Ginkgo biloba, St. John's wort, and peppermint. We summarized and characterized the adverse event reports received, focusing on the composition of the DBSs and the nature of associated adverse events. We also cross-referenced reported single-ingredient DBSs with corresponding available product information. A sample of CAERS cases associated with signal DBSs was also characterized in detail. RESULTS: CAERS reports involving ginseng DBSs were most frequently reported during the study period, whereas reports involving St. John's wort were the least frequently reported. Most CAERS reports involved multiple-ingredient DBSs, and 3-13% of reports involved multiple DBSs. Gastrointestinal and neurologic problems were the most common clinical outcomes among single-ingredient DBS-associated adverse events. CONCLUSIONS: CAERS surveillance of DBS adverse effects is potentially as effective as other passive surveillance methods, but the number of reports is relatively small, validation is incomplete, and some inconsistencies within reports were found. Reports in CAERS may underrepresent DBS adverse events associated with DBS consumption.
Assuntos
Sistemas de Notificação de Reações Adversas a Medicamentos/normas , Suplementos Nutricionais/efeitos adversos , Suplementos Nutricionais/normas , Vigilância de Produtos Comercializados/normas , United States Food and Drug Administration/normas , Sistemas de Notificação de Reações Adversas a Medicamentos/tendências , Echinacea/efeitos adversos , Alho/efeitos adversos , Ginkgo biloba/efeitos adversos , Hypericum/efeitos adversos , Mentha piperita/efeitos adversos , Panax/efeitos adversos , Vigilância de Produtos Comercializados/tendências , Estados Unidos , United States Food and Drug Administration/tendênciasAssuntos
Resfriado Comum/tratamento farmacológico , Echinacea , Fitoterapia , Extratos Vegetais/uso terapêutico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Resfriado Comum/imunologia , Echinacea/efeitos adversos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fitoterapia/efeitos adversos , Efeito Placebo , Extratos Vegetais/efeitos adversos , Estudos Prospectivos , Índice de Gravidade de Doença , Adulto JovemRESUMO
Herbal products and dietary supplements are complementary and alternative medicine (CAM) therapies that have grown faster than any other CAM treatments. Little information is available about the use of these products in the stage 5 chronic kidney disease (CKD) population. Information on the use, safety, efficacy, adverse effects, and recommended dosages in the nondialysis population are summarized in this article.
Assuntos
Suplementos Nutricionais , Falência Renal Crônica/prevenção & controle , Fitoterapia/efeitos adversos , Fitoterapia/métodos , Sulfatos de Condroitina/efeitos adversos , Sulfatos de Condroitina/uso terapêutico , Suplementos Nutricionais/efeitos adversos , Suplementos Nutricionais/estatística & dados numéricos , Serviços de Informação sobre Medicamentos , Echinacea/efeitos adversos , Óleos de Peixe/efeitos adversos , Óleos de Peixe/uso terapêutico , Alho/efeitos adversos , Ginkgo biloba/efeitos adversos , Glucosamina/efeitos adversos , Glucosamina/uso terapêutico , Interações Ervas-Drogas , Humanos , Hypericum/efeitos adversos , Falência Renal Crônica/complicações , Falência Renal Crônica/psicologia , Panax/efeitos adversos , Aceitação pelo Paciente de Cuidados de Saúde/psicologia , Aceitação pelo Paciente de Cuidados de Saúde/estatística & dados numéricos , Seleção de Pacientes , Fitoterapia/psicologia , Índice de Gravidade de DoençaRESUMO
Echinacea spp. are native to North America and were traditionally used by the Indian tribes for a variety of ailments, including mouth sores, colds and snake-bites. The three most commonly used Echinacea spp. are E. angustifolia, E. pallida and E. purpurea. Systematic literature searches were conducted in six electronic databases and the reference lists of all of the papers located were checked for further relevant publications. Information was also sought from the spontaneous reporting programmes of the WHO and national drug safety bodies. Twenty-three manufacturers of echinacea were contacted and asked for data held on file. Finally our own departmental files were searched. No language restrictions were imposed. Combination products and homeopathic preparations were excluded. Data from clinical studies and spontaneous reporting programmes suggest that adverse events with echinacea are not commonly reported. Gastrointestinal upsets and rashes occur most frequently. However, in rare cases, echinacea can be associated with allergic reactions that may be severe. Although there is a large amount of data that investigates the efficacy of echinacea, safety issues and the monitoring of adverse events have not been focused on. Short-term use of echinacea is associated with a relatively good safety profile, with a slight risk of transient, reversible, adverse events. The association of echinacea with allergic reactions is supported by the present evaluation. While these reactions are likely to be rare, patients with allergy or asthma should carefully consider their use of echinacea. The use of echinacea products during pregnancy and lactation would appear to be ill-advised in light of the paucity of data in this area.
Assuntos
Sistemas de Notificação de Reações Adversas a Medicamentos/estatística & dados numéricos , Echinacea/efeitos adversos , Fitoterapia/efeitos adversos , Preparações de Plantas/efeitos adversos , Adulto , Criança , Pré-Escolar , Ensaios Clínicos como Assunto , Europa (Continente) , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estados UnidosRESUMO
The neurohormone, melatonin, a product of the pineal gland, is a potent immune cell stimulant. Phytochemicals contained in root extracts of the plant species Echinacea purpurea are also potent as immune cell stimulants. Both agents are potent stimulants of T, B, and/or natural killer cells, but little is known of their effect on other hemopoietic cells, specifically granular leukocytes, also participants in a wide variety of disease defense processes. Given their current popularity and availability for amelioration of a) jet lag and sleep disorders (melatonin) and b) virus-mediated respiratory infections (E. purpurea), we investigated the effects of these agents on granular leukocytes and their precursors, myeloid cells. Mice received these agents daily for 7 or 14 days via the diet, thus mimicking human administration, after which spleens and bone marrow were removed and assessed for mature, differentiated granulocytes and their myeloid progenitors. The influence of these agents was directly related to the stage of cell maturity. Administration of both agents together resulted in significantly elevated levels of myeloid progenitor cells in both bone marrow and spleen and significantly reduced levels of mature, functional granulocyte progeny in both organs, suggesting a) increased precursor proliferation, b) antiapoptosis among the progenitors, and/or c) inhibition of precursor maturation-the latter readily explaining the paucity of mature granulocyte progeny. In conclusion, individual administration of either the herbal derivative and melatonin was either without effect (E. purpurea) or even advantageous (melatonin) to cells of this lineage, but when administered together, these agents significantly perturbed myelopoiesis.
Assuntos
Echinacea/efeitos adversos , Melatonina/efeitos adversos , Células Mieloides/efeitos dos fármacos , Plantas Medicinais , Animais , Células da Medula Óssea/efeitos dos fármacos , Contagem de Células , Interações Medicamentosas , Granulócitos/efeitos dos fármacos , Leucopoese/efeitos dos fármacos , Masculino , Camundongos , Camundongos Endogâmicos DBA , Baço/citologia , Baço/efeitos dos fármacosRESUMO
BACKGROUND: Echinacea purpurea stimulates the immune response and is promoted to reduce symptom severity and the duration of upper respiratory tract infections. We sought to determine the efficacy of a standardized preparation of E purpurea in reducing symptom severity and duration of the common cold. METHODS: A randomized, double-blind, placebo-controlled design was used. Patients received either 100 mg of E purpurea (freeze-dried pressed juice from the aerial portion of the plant) or a lactose placebo 3 times daily until cold symptoms were relieved or until the end of 14 days, whichever came first. Symptoms (sneezing, nasal discharge, nasal congestion, headache, sore or scratchy throat, hoarseness, muscle aches, and cough) were scored subjectively by the patient and recorded daily in a diary. Kaplan-Meier curves were used to estimate the survival function of time to resolution in each group. The Wilcoxon rank sum test was used to compare time to resolution between the 2 groups. RESULTS: One hundred twenty-eight patients were enrolled within 24 hours of cold symptom onset. Group demographic distribution was comparable for sex, age, time from symptom onset to enrollment in the study, average number of colds per year, and smoking history. No statistically significant difference was observed between treatment groups for either total symptom scores (P range,.29-.90) or mean individual symptom scores (P range,.09-.93). The time to resolution of symptoms was not statistically different (P =.73). CONCLUSIONS: Some studies have concluded that Echinacea effectively reduces the symptoms and duration of the common cold. We were unable to replicate such findings. Further studies using different preparations and dosages of E purpurea are necessary to validate previous claims.
Assuntos
Resfriado Comum/tratamento farmacológico , Echinacea , Fitoterapia , Adolescente , Adulto , Método Duplo-Cego , Echinacea/efeitos adversos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Componentes Aéreos da Planta , Estudos Prospectivos , Falha de TratamentoRESUMO
BACKGROUND: Echinacea products are among the most popular phytomedicines on the North American market. Since at least half of all pregnancies are unplanned, many women inadvertently use echinacea in their first trimester. Presently, there is a paucity of information regarding the gestational safety of this herb. The primary objective of this study was to evaluate the safety of echinacea in pregnancy when used for upper respiratory tract ailments. PATIENTS AND METHODS: The study group consisted of women who were prospectively followed up after contacting the Motherisk Program regarding the gestational use of echinacea. This cohort was disease-matched to women exposed to nonteratogenic agents by maternal age, alcohol, and cigarette use. Rates of major and minor malformations between the groups were compared. RESULTS: A total of 206 women were enrolled in the study group after using echinacea products during pregnancy; 112 women used the herb in the first trimester. There were a total of 195 live births, including 3 sets of twins, 13 spontaneous abortions, and 1 therapeutic abortion. Six major malformations were reported, including 1 chromosomal abnormality, and 4 of these malformations occurred with echinacea exposure in the first trimester. In the control group, there were 206 women with 198 live births, 7 spontaneous abortions, and 1 therapeutic abortion. Seven major malformations were reported. There were no statistical differences between the study and control groups for any of the end points analyzed. CONCLUSIONS: This first prospective study suggests that gestational use of echinacea during organogenesis is not associated with an increased risk for major malformations.
Assuntos
Echinacea/efeitos adversos , Plantas Medicinais , Complicações na Gravidez/epidemiologia , Complicações na Gravidez/etiologia , Resultado da Gravidez , Anormalidades Congênitas/epidemiologia , Anormalidades Congênitas/etiologia , Feminino , Humanos , Recém-Nascido , Gravidez , Estudos ProspectivosRESUMO
Despite the widespread use of herbal medicines, documented herb-drug interactions are sparse. We have reviewed the literature to determine the possible interactions between the seven top-selling herbal medicines (ginkgo, St John's wort, ginseng, garlic, echinacea, saw palmetto and kava) and prescribed drugs. Literature searches were performed using the following databases: Medline (via Pubmed), Cochrane Library, Embase and phytobase (all from their inception to July 2000). All data relating to herb-drug interactions were included regardless of whether they were based on case reports, case series, clinical trials or other types of investigation in humans. In vitro experiments were excluded. Data were extracted by the first author and validated by the second author. 41 case reports or case series and 17 clinical trials were identified. The results indicate that St John's wort (Hypericum perforatum) lowers blood concentrations of cyclosporin, amitriptyline, digoxin, indinavir, warfarin, phenprocoumon and theophylline; furthermore it causes intermenstrual bleeding, delirium or mild serotonin syndrome, respectively, when used concomitantly with oral contraceptives (ethinylestradiol/desogestrel), loperamide or selective serotonin-reuptake inhibitors (sertaline, paroxetine, nefazodone). Ginkgo (Ginkgo biloba) interactions include bleeding when combined with warfarin, raised blood pressure when combined with a thiazide diuretic and coma when combined with trazodone. Ginseng (Panax ginseng) lowers blood concentrations of alcohol and warfarin, and induces mania if used concomitantly with phenelzine. Garlic (Allium sativum) changes pharmacokinetic variables of paracetamol, decreases blood concentrations of warfarin and produces hypoglycaemia when taken with chlorpropamide. Kava (Piper methysticum) increases 'off' periods in Parkinson patients taking levodopa and can cause a semicomatose state when given concomitantly with alprazolam. No interactions were found for echinacea (Echinacea angustifolia, E. purpurea, E. pallida) and saw palmetto (Serenoa repens). In conclusion, interactions between herbal medicines and synthetic drugs exist and can have serious clinical consequences. Healthcare professionals should ask their patients about the use of herbal products and consider the possibility of herb-drug interactions.
Assuntos
Interações Medicamentosas , Prescrições de Medicamentos , Fitoterapia/efeitos adversos , Preparações de Plantas/efeitos adversos , Echinacea/efeitos adversos , Alho/efeitos adversos , Ginkgo biloba/efeitos adversos , Interações Ervas-Drogas , Humanos , Hypericum/efeitos adversos , Kava/efeitos adversos , Panax/efeitos adversos , Extratos Vegetais/efeitos adversos , Preparações de Plantas/farmacocinética , SerenoaRESUMO
BACKGROUND: Evidence for the scientific basis of purported therapeutic effects and adverse effects of herbal supplements continues to grow. Many herbal supplements are touted for their immunostimulatory properties, and both in vitro and in vivo experiments have supported this claim. Although this explains their beneficial effects in preventing or curtailing disease, to our knowledge, no immunostimulatory herbal supplements have been reported to exacerbate disorders of immune system overactivity. OBSERVATIONS: We describe 3 patients whose autoimmune disease onset and/or flares correlated with ingestion of herbal supplements with proven immunostimulatory effects. Echinacea and the alga Spirulina platensis are implicated in 2 patients' flares of pemphigus vulgaris, and a supplement containing the algae Spirulina platensis and Aphanizomenon flos-aquae was ingested by a third patient days before both onset and a severe flare of dermatomyositis. The third patient showed heterozygosity for a tumor necrosis factor alpha (TNF-alpha) promoter polymorphism (-308A), leading to increased production of TNF-alpha, which may have predisposed her to developing dermatomyositis. CONCLUSIONS: Immunostimulatory herbal supplements may exacerbate preexisting autoimmune disease or precipitate autoimmune disease in persons genetically predisposed to such disorders. Increased production of TNF-alpha may play a role, although more research is needed to clarify the mechanisms of such phenomena.
Assuntos
Doenças Autoimunes/induzido quimicamente , Doenças Autoimunes/diagnóstico , Eritema/induzido quimicamente , Eritema/diagnóstico , Fitoterapia , Preparações de Plantas/efeitos adversos , Plantas Medicinais , Doenças Autoimunes/patologia , Proteínas de Bactérias/efeitos adversos , Cianobactérias , Diagnóstico Diferencial , Suplementos Nutricionais , Echinacea/efeitos adversos , Eritema/patologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , SpirulinaRESUMO
Skin disorders are the most common adverse reactions attributed to drugs. Any skin disorder can be imitated, induced or aggravated by drugs. To help you keep up-to-date with the very latest skin reactions occurring with both new and established drugs, this section of the journal brings you information selected from the adverse drug reaction alerting service Reactions Weekly. The following case reports are selected from the very latest to be published in the world dermatology literature. Any claim of a first report has been verified by a search of AdisBase (a proprietary database of Adis International, Auckland, New Zealand) and Medline. Each case report is assessed for seriousness using the FDA MedWatch definition of serious (patient outcome is: death; life-threatening; hospitalization; disability; congenital anomaly; or requires intervention to prevent permanent impairment or damage).